Hyperactivity and Reduced Activation of Anterior Hippocampus in Early Psychosis

American Journal of Psychiatry, Ahead of Print.
Source: American Journal of Psychiatry - Category: Psychiatry Authors: Source Type: research

Related Links:

This study demonstrated that mTORC2 subunit, RICTOR, and p-AKT (Ser473) have hyperactivity in esophageal squamous cell carcinoma (ESCC) and promotes its development. Moreover, down-regulation of RICTOR can improve the sensitivity of ESCC cells to the pan-mTOR inhibitor PP242 as well as mTORC1 inhibitor RAD001.
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
Researchers have shown clear connections between the opioid epidemic and increase of pharmaceutical company payments to doctors. Now, new research shows a similar phenomenon with prescribing stimulants to children with attention deficit hyperactivity disorder. A study published by researchers at Boston Medical Center’s Grayken Center for Addiction in JAMA Pediatrics, found that stimulant drug manufacturers are interacting with doctors frequently. From 2014 to 2018, the industry offered food or…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
In this study, we examined the clinical and psychosocial characteristics of youth at familial and clinical high risk (HR) for BD, and compared these characteristics to those of youth with BD I and II. Both groups were recruited based on current, active mood symptoms from separate randomized trials of family therapy. A total of 127 HR youth were evaluated: 52 (40.9%) were diagnosed with BD-NOS and 75 (59.1%) were diagnosed with MDD. Compared to adolescents with BD I and II (n=145), HR youth had higher rates of anxiety disorders, and comparable rates of attention-deficit/hyperactivity disorder and oppositional defiant disord...
Source: Journal of Psychiatric Research - Category: Psychiatry Source Type: research
Publication date: Available online 25 January 2020Source: Neuroscience &Biobehavioral ReviewsAuthor(s): Anna Kaiser, Pascal-M. Aggensteiner, Sarah Baumeister, Nathalie E. Holz, Tobias Banaschewski, Daniel BrandeisAbstractThe current meta-analysis summarizes relevant literature on earlier (P100, N100, P200, N200, ERN/Ne) versus later (P300, Pe, CNV) cognitive Event-Related Potential (ERP) differences between children, adolescents, and adults with Attention-Deficit/Hyperactivity Disorder (ADHD) and without ADHD (non-ADHD). Furthermore, the heterogeneity in previous research is addressed by analyzing potentially relevant ...
Source: Neuroscience and Biobehavioral Reviews - Category: Neuroscience Source Type: research
.
Source: Ophthalmic Epidemiology - Category: Opthalmology Authors: Source Type: research
Publication date: Available online 23 January 2020Source: Cancer CellAuthor(s): Dhivya R. Sudhan, Angel Guerrero-Zotano, Helen Won, Paula González Ericsson, Alberto Servetto, Mariela Huerta-Rosario, Dan Ye, Kyung-min Lee, Luigi Formisano, Yan Guo, Qi Liu, Lisa N. Kinch, Monica Red Brewer, Teresa Dugger, James Koch, Michael J. Wick, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan AuerbachSummaryWe developed neratinib-resistant HER2-mutant cancer cells by gradual dose escalation. RNA sequencing identified TORC1 signaling as an actionable mechanism of drug resistance. Primary and acquired neratinib resistance ...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
.
Source: International Journal of Neuroscience - Category: Neuroscience Authors: Source Type: research
Dexmethylphenidate, and potentially other methylphenidates used in the treatment of attention deficit hyperactivity disorder (ADHD), may cause severe muscle pain and stiffness. Medication side effects should be considered as the possible cause if a patient with ADHD develops severe symptoms. AbstractDexmethylphenidate, and potentially other methylphenidates used in the treatment of attention deficit hyperactivity disorder (ADHD), may cause severe muscle pain and stiffness. Medication side effects should be considered as the possible cause if a patient with ADHD develops severe symptoms.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
Authors: Childress A, Hoo-Cardiel A, Lang P Abstract Introduction: Attention-deficit/hyperactivity disorder (ADHD) commonly occurs in children, adolescents, and adults. Although symptoms of ADHD often respond robustly to treatment with stimulants (amphetamine or methylphenidate), not all patients are appropriate candidates for treatment with these drugs. Guanfacine extended-release (GXR) is a non-stimulant alternative drug approved for the treatment of ADHD in the United States (U.S.), Canada, and Europe.Areas covered: The chemistry, pharmacokinetics, mechanism of action and dosage of GXR are presented. Efficacy an...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Publication date: Available online 23 January 2020Source: The LancetAuthor(s): Jonathan Posner, Guilherme V Polanczyk, Edmund Sonuga-BarkeSummaryAttention-deficit hyperactivity disorder (ADHD), like other psychiatric disorders, represents an evolving construct that has been refined and developed over the past several decades in response to research into its clinical nature and structure. The clinical presentation and course of the disorder have been extensively characterised. Efficacious medication-based treatments are available and widely used, often alongside complementary psychosocial approaches. However, their effectiv...
Source: The Lancet - Category: General Medicine Source Type: research
More News: Hyperactivity | Psychiatry